IA
AQST icon

IndexIQ Advisors’s Aquestive Therapeutics AQST Stock Holding History

IndexIQ Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-81,213
Closed -$316K – 1321
2021
Q4 		$316K Sell
81,213
-5,248
-6% -$26.3K 0.01% 924
2021
Q3 		$377K Buy
86,461
+8,660
+11% +$34K 0.01% 869
2021
Q2 		$309K Sell
77,801
-11,589
-13% -$46.3K 0.01% 969
2021
Q1 		$465K Buy
+89,390
New +$476K 0.02% 391

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
GL
Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

IndexIQ Advisors's AQST Position: Q1 2022 in Review

IndexIQ Advisors sold out of Aquestive Therapeutics (AQST) in Q1 2022, closing a stake of 81,213 shares — an estimated $316K sold.

IndexIQ Advisors first reported a position in AQST in Q1 2021 and held it in 4 quarters. The position peaked at $465K in Q1 2021. 51 funds tracked by Wall St. Rank hold AQST as of Q1 2022.

  • IndexIQ Advisors reported no remaining Aquestive Therapeutics position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 81,213 Aquestive Therapeutics shares in Q1 2022, an estimated $316K.
  • IndexIQ Advisors first reported a position in Aquestive Therapeutics in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's Aquestive Therapeutics position peaked at $465K in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.